Update on cutaneous mesenchymal tumors in the 5th edition of WHO classification of skin tumors with an emphasis on new fusion-associated neoplasms

IF 3.4 3区医学 Q1 PATHOLOGY

Virchows Archiv Pub Date : 2024-09-12 DOI:10.1007/s00428-024-03925-2

Antonina V. Kalmykova, Vira Baranovska-Andrigo, Michael Michal

引用次数: 0

Abstract

The section on mesenchymal tumors in the 5th edition of WHO classification of skin tumors has undergone several changes, the most important of which is the inclusion of newly identified tumor entities, which will be the main focus of this review article. These specifically include three novel cutaneous mesenchymal tumors with melanocytic differentiation, and rearrangements of the CRTC1::TRIM11, ACTIN::MITF, and MITF::CREM genes as well as EWSR1::SMAD3-rearranged fibroblastic tumors, superficial CD34-positive fibroblastic tumors, and NTRK-rearranged spindle cell neoplasms. Some of the other most important changes will be briefly mentioned as well.

Abstract Image

查看原文本刊更多论文

更新第五版世界卫生组织皮肤肿瘤分类中的皮肤间质肿瘤，重点关注新的融合相关肿瘤

第五版《世界卫生组织皮肤肿瘤分类》中有关间质肿瘤的部分经历了多次修改，其中最重要的是纳入了新发现的肿瘤实体，这将是本综述文章的重点。这些肿瘤具体包括三种具有黑素细胞分化的新型皮肤间质瘤，CRTC1::TRIM11、ACTIN::MITF 和 MITF:CREM 基因重排，以及 EWSR1::SMAD3重排的成纤维细胞瘤、浅表 CD34 阳性成纤维细胞瘤和 NTRK 重排的纺锤形细胞瘤。其他一些最重要的变化也将简要提及。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Virchows Archiv 医学-病理学

CiteScore

7.40

自引率

2.90%

发文量

204

审稿时长

4-8 weeks

期刊介绍： Manuscripts of original studies reinforcing the evidence base of modern diagnostic pathology, using immunocytochemical, molecular and ultrastructural techniques, will be welcomed. In addition, papers on critical evaluation of diagnostic criteria but also broadsheets and guidelines with a solid evidence base will be considered. Consideration will also be given to reports of work in other fields relevant to the understanding of human pathology as well as manuscripts on the application of new methods and techniques in pathology. Submission of purely experimental articles is discouraged but manuscripts on experimental work applicable to diagnostic pathology are welcomed. Biomarker studies are welcomed but need to abide by strict rules (e.g. REMARK) of adequate sample size and relevant marker choice. Single marker studies on limited patient series without validated application will as a rule not be considered. Case reports will only be considered when they provide substantial new information with an impact on understanding disease or diagnostic practice.